HRP20180815T8 - Prolijekovi fosforamidne kiseline 5-[5-fenil-4-(piridin-2-ilmetilamino)hinazolin-2-il]piridin-3-sulfonamida - Google Patents

Prolijekovi fosforamidne kiseline 5-[5-fenil-4-(piridin-2-ilmetilamino)hinazolin-2-il]piridin-3-sulfonamida

Info

Publication number
HRP20180815T8
HRP20180815T8 HRP20180815TT HRP20180815T HRP20180815T8 HR P20180815 T8 HRP20180815 T8 HR P20180815T8 HR P20180815T T HRP20180815T T HR P20180815TT HR P20180815 T HRP20180815 T HR P20180815T HR P20180815 T8 HRP20180815 T8 HR P20180815T8
Authority
HR
Croatia
Prior art keywords
ylmethylamino
quinazolin
sulfonamide
pyridin
pyridine
Prior art date
Application number
HRP20180815TT
Other languages
English (en)
Croatian (hr)
Inventor
Jayakumar S. Warrier
Navnath Dnyanoba Yadav
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20180815T1 publication Critical patent/HRP20180815T1/hr
Publication of HRP20180815T8 publication Critical patent/HRP20180815T8/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509Six-membered rings
    • C07F9/6512Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65128Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20180815TT 2012-06-11 2013-06-10 Prolijekovi fosforamidne kiseline 5-[5-fenil-4-(piridin-2-ilmetilamino)hinazolin-2-il]piridin-3-sulfonamida HRP20180815T8 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261657913P 2012-06-11 2012-06-11
PCT/US2013/044882 WO2013188254A1 (en) 2012-06-11 2013-06-10 Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide
EP13730444.0A EP2858987B1 (en) 2012-06-11 2013-06-10 Phosphoramidic acid prodrugs of 5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide

Publications (2)

Publication Number Publication Date
HRP20180815T1 HRP20180815T1 (hr) 2018-06-29
HRP20180815T8 true HRP20180815T8 (hr) 2019-02-08

Family

ID=48670111

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180815TT HRP20180815T8 (hr) 2012-06-11 2013-06-10 Prolijekovi fosforamidne kiseline 5-[5-fenil-4-(piridin-2-ilmetilamino)hinazolin-2-il]piridin-3-sulfonamida

Country Status (34)

Country Link
US (1) US9238666B2 (https=)
EP (1) EP2858987B1 (https=)
JP (1) JP6234450B2 (https=)
KR (1) KR102092984B1 (https=)
CN (1) CN104350048B (https=)
AR (1) AR091402A1 (https=)
AU (1) AU2013274619B2 (https=)
BR (1) BR112014030629B1 (https=)
CA (1) CA2876359C (https=)
CL (1) CL2014003361A1 (https=)
CO (1) CO7160032A2 (https=)
CY (1) CY1120432T1 (https=)
DK (1) DK2858987T3 (https=)
EA (1) EA024692B1 (https=)
ES (1) ES2675314T3 (https=)
HR (1) HRP20180815T8 (https=)
HU (1) HUE039210T2 (https=)
IL (1) IL236074A (https=)
LT (1) LT2858987T (https=)
MX (1) MX356699B (https=)
MY (1) MY169219A (https=)
NZ (1) NZ703632A (https=)
PE (1) PE20150228A1 (https=)
PH (1) PH12014502747B1 (https=)
PL (1) PL2858987T3 (https=)
PT (1) PT2858987T (https=)
RS (1) RS57376B1 (https=)
SG (1) SG11201408076WA (https=)
SI (1) SI2858987T1 (https=)
SM (1) SMT201800369T1 (https=)
TN (1) TN2014000499A1 (https=)
TW (1) TWI571470B (https=)
WO (1) WO2013188254A1 (https=)
ZA (1) ZA201500161B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
WO2014143606A1 (en) * 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
JP6386527B2 (ja) * 2013-03-11 2018-09-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company カリウムイオンチャネル阻害剤としてのピロロピリダジン
US20180318268A1 (en) * 2015-11-19 2018-11-08 Biohaven Pharmaceutical Holding Company Ltd. Amine prodrugs of pharmaceutical compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
GB9514380D0 (en) * 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
HUP0104634A3 (en) 1998-07-06 2002-11-28 Bristol Myers Squibb Co Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
ES2215474B1 (es) 2002-12-24 2005-12-16 J. URIACH & CIA S.A. Nuevos derivados de fosforamida.
AR049847A1 (es) 2004-07-29 2006-09-06 Merck & Co Inc Inhibidores de los canales de potasio
EP1838690A2 (en) * 2004-12-21 2007-10-03 Devgen N.V. Compounds with kv4 ion channel activity
EA021113B1 (ru) 2009-09-03 2015-04-30 Бристол-Майерс Сквибб Кампани Хиназолины в качестве ингибиторов калиевых каналов
CN102984941B (zh) 2009-09-04 2016-08-17 密执安大学评议会 用于治疗白血病的组合物和方法
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
ES2691671T3 (es) * 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
US9242966B2 (en) * 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
WO2014143609A1 (en) * 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors

Also Published As

Publication number Publication date
TWI571470B (zh) 2017-02-21
HUE039210T2 (hu) 2018-12-28
JP6234450B2 (ja) 2017-11-22
IL236074A (en) 2016-08-31
CY1120432T1 (el) 2019-07-10
ZA201500161B (en) 2017-04-26
KR20150023667A (ko) 2015-03-05
WO2013188254A1 (en) 2013-12-19
RS57376B1 (sr) 2018-08-31
CA2876359C (en) 2020-01-21
EP2858987A1 (en) 2015-04-15
AR091402A1 (es) 2015-02-04
AU2013274619A1 (en) 2015-01-29
US20150175641A1 (en) 2015-06-25
KR102092984B1 (ko) 2020-03-24
TW201402592A (zh) 2014-01-16
CL2014003361A1 (es) 2015-05-29
SG11201408076WA (en) 2015-01-29
EA201492256A1 (ru) 2016-05-31
HK1203928A1 (en) 2015-11-06
MX2014014525A (es) 2015-02-24
BR112014030629A2 (pt) 2017-06-27
SMT201800369T1 (it) 2018-09-13
PL2858987T3 (pl) 2018-08-31
EP2858987B1 (en) 2018-04-25
BR112014030629B1 (pt) 2021-12-21
MX356699B (es) 2018-06-11
MY169219A (en) 2019-03-19
PE20150228A1 (es) 2015-02-19
TN2014000499A1 (en) 2016-03-30
NZ703632A (en) 2016-01-29
PH12014502747A1 (en) 2015-02-02
PT2858987T (pt) 2018-07-04
HRP20180815T1 (hr) 2018-06-29
ES2675314T3 (es) 2018-07-10
EA024692B1 (ru) 2016-10-31
IL236074A0 (en) 2015-02-01
SI2858987T1 (en) 2018-06-29
DK2858987T3 (en) 2018-07-30
LT2858987T (lt) 2018-07-10
JP2015521598A (ja) 2015-07-30
PH12014502747B1 (en) 2015-02-02
US9238666B2 (en) 2016-01-19
CO7160032A2 (es) 2015-01-15
CN104350048A (zh) 2015-02-11
CA2876359A1 (en) 2013-12-19
CN104350048B (zh) 2016-12-07
AU2013274619B2 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
IL270262A (en) Nucleic acids for treatment of allergies
CL2014003498A1 (es) Carboxamidas heterocíclicas fungicidas
DK3679922T4 (da) Sprøjte
DK3381444T3 (da) Sprøjte
EP2832391A4 (en) SYRINGE
EP2914731A4 (en) REVERSIBLE GENE EXPRESSION
EP2913076A4 (en) SYRINGE
EP2883547A4 (en) MEDICINE
HRP20180815T1 (hr) Prolijekovi fosforamidne kiseline 5-[5-fenil-4-(piridin-2-ilmetilamino)hinazolin-2-il]piridin-3-sulfonamida
UA25176S (uk) Сервант
UA25009S (uk) Сервант
FR2987422B1 (fr) Plateforme stabilisee
TH1401001018B (th) ชิ้นส่วนลดทอนปริมาณเหลือ
TH148762B (th) อนุพันธ์ของพิร์โรลิดีน-3-อิลแอซีติก แอซิด
UA25012S (uk) Сервант комбінований
UA25006S (uk) Сервант кутовий
EP2885023A4 (en) SYRINGE